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Tubular damage following ischemic renal injury is often reversible, and tubular epithelial cell (TEC) prolif-
eration is a hallmark of tubular repair. Macrophages have been implicated in tissue repair, and CSF-1, the 
principal macrophage growth factor, is expressed by TECs. We therefore tested the hypothesis that CSF-1 
is central to tubular repair using an acute renal injury and repair model, ischemia/reperfusion (I/R). Mice 
injected with CSF-1 following I/R exhibited hastened healing, as evidenced by decreased tubular pathology, 
reduced fibrosis, and improved renal function. Notably, CSF-1 treatment increased TEC proliferation and 
reduced TEC apoptosis. Moreover, administration of a CSF-1 receptor–specific (CSF-1R–specific) antibody 
after I/R increased tubular pathology and fibrosis, suppressed TEC proliferation, and heightened TEC apop-
tosis. To determine the contribution of macrophages to CSF-1–dependent renal repair, we assessed the effect 
of CSF-1 on I/R in mice in which CD11b+ cells were genetically ablated and determined that macrophages only 
partially accounted for CSF-1–dependent tubular repair. We found that TECs expressed the CSF-1R and that 
this receptor was upregulated and coexpressed with CSF-1 in TECs following renal injury in mice and humans. 
Furthermore, signaling via the CSF-1R stimulated proliferation and reduced apoptosis in human and mouse 
TECs. Taken together, these data suggest that CSF-1 mediates renal repair by both a macrophage-dependent 
mechanism and direct autocrine/paracrine action on TECs.
????????????
The kidney possesses a remarkable capacity to regenerate. Follow-
ing acute kidney injury and subsequent inflammation, the injured 
kidney often heals (1). As inflammation and repair are closely inter-
twined, renal inflammation sets the stage for a dynamic repair pro-
cess (2). Repair begins during the early phases of inflammation but 
only reaches completion after the injurious influence is eliminated 
(3). Although the pathogenesis of acute kidney injury is in part 
dependent on the etiology, ischemia is often a consistent feature 
(reviewed in ref. 4). Tubules are notably sensitive to acute renal isch-
emia. The tubules in the outer stripe of the outer medulla are most 
susceptible to ischemic injury (5). The mouse model of ischemia/
reperfusion (I/R) is a particularly powerful tool for identifying the 
molecular mechanisms central to repair. When acute kidney injury 
is sufficiently severe, it leads to morbidity and mortality. Although 
acute renal injury is common, there are few therapeutic approach-
es (6). Therefore, deciphering the mechanisms that promote renal 
healing and in particular tubular repair using I/R in mice may offer 
the promise of new therapeutic strategies for acute renal injury.
There are several possible mechanisms that may be responsible 
for tubular repair following injury. These include bone marrow 
cells directly replacing damaged tubules and intrinsic tubular 
epithelial cells (TECs) replenishing damaged tubules. We can 
rule out bone marrow cells directly replacing damaged tubules, 
as restoration of TECs during the repair of postischemic kidneys 
occurs independently of bone marrow–derived stem cells (7). 
Moreover, genetic fate-mapping techniques indicate that surviv-
ing TECs proliferate and replenish necrotic and apoptotic tubules 
following ischemic tubular injury (1). In fact, TEC proliferation 
is a hallmark of renal repair. For healing to advance, accompany-
ing the replenishment of TECs, simultaneous mechanisms must 
halt further TEC destruction. Thus, the molecular pathways that 
promote TEC proliferation and halt TEC destruction following 
renal injury need to be elucidated.
Macrophages are instrumental in inflammation. CSF-1 is a 
hematopoietic growth factor that binds to a sole receptor, CSF-1 
receptor (CSF-1R), expressed on macrophages (8, 9). During 
renal inflammation (lupus nephritis, unilateral ureter obstruc-
tion [UUO]), CSF-1 is generated predominantly by TECs (10, 11). 
Using mutant mice lacking CSF-1, we established that CSF-1 
promotes macrophage-dependent renal inflammation (10). 
CSF-1 fosters the intrarenal recruitment, proliferation, and acti-
vation of macrophages that in turn release mediators respon-
sible for inducing apoptosis of TECs (10). Thus, CSF-1 fuels 
the intrarenal accumulation of macrophages that are central to 
initiating renal inflammation. However, these findings are lim-
ited to models of inflammation in which the offending influ-
ence (autoimmune disease, obstruction) is not eliminated; thus, 
inflammation escalates and healing is prevented. In contrast, in 
a setting of ischemia-induced heart failure, autologous engraft-
ment of CSF-1–transfected myoblasts improved the repair of the 
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failing myocardium (12). This suggests that when the offending 
influence is transient, CSF-1 fosters tissue repair.
Nonhematopoietic and hematopoietic cells may contribute to 
CSF-1–dependent tissue repair. Growing evidence suggests that 
tissue repair is mediated by macrophages, as these CSF-1R–bear-
ing cells switch their phenotype from tissue destroyers to regen-
erators (reviewed in refs. 13, 14). While macrophages dependent 
on CSF-1 are implicated in renal repair, the contribution of 
parenchymal cells to CSF-1–dependent renal repair has not been 
considered. Evidence suggests that epithelial and other cells may 
be regulated by CSF-1 in an autocrine or paracrine manner. Akin 
to TECs in the inflamed kidney, mammary epithelial cells express 
CSF-1, and during pregnancy, they also express the CSF-1R (15). 
Moreover, signaling via the CSF-1R stimulates proliferation of 
epithelial carcinoma cells and several other cell types (macro-
phages, myoblasts) and is central to breast remodeling during 
pregnancy (16, 17). This raises the possibility that CSF-1R expres-
sion on CSF-1–expressing TECs mediates tubular repair. We 
hypothesized that CSF-1 hastens renal repair in a model of renal 
injury with a transient insult, I/R. Furthermore, we hypothesized 
that CSF-1–dependent renal repair is only partially mediated by 
macrophages and that a macrophage-independent autocrine/
paracrine mechanism leads to renal tubular repair.
We now report that administration of CSF-1 after renal injury 
fosters improved renal tubular pathology and renal function, 
decreases renal fibrosis, accelerates the rate of tubular prolifera-
tion, and suppresses tubular apoptosis. Genetic ablation on mac-
rophages revealed that macrophages are only partially responsible 
for CSF-1—dependent renal repair. Investigating whether CSF-1 
signaling on TEC directly mediates renal repair, we determined 
that TECs express the CSF-1R and that this receptor is upregulated 
and coexpressed with CSF-1 on TEC during acute renal injury in 
mice and humans. Signaling via this CSF-1R on TEC stimulates 
TEC proliferation and dampens TEC apoptosis. Thus, we have 
identified a CSF-1–dependent, macrophage-independent auto-
crine/paracrine mechanism in tubules that is instrumental in 
tubular self repair following acute renal injury.
???????
CSF-1 mediates repair during I/R. Since CSF-1 is instrumental in 
renal inflammation (10, 18–20) and inflammation sets the stage 
for repair, we hypothesized that CSF-1 promotes kidney repair. 
To test this hypothesis, we used a model of renal ischemic injury 
and repair. Tubules in the outer medulla are notably sensitive to 
ischemia and are readily damaged, often with sufficient severity to 
result in death. However, the kidney is resilient, and most often the 
damaged tubules regenerate and the kidney repairs. This process 
is rapid and the pathology peaks by 2–3 days; repair is evident by 5 
days following I/R (Supplemental Figure 1A; supplemental mate-
rial available online with this article; doi:10.1172/JCI39087DS1). 
To determine whether CSF-1 accelerates healing, we selected a time 
point to evaluate mice following I/R at which repair is evident but 
incomplete (5 days). Using this model, we injected CSF-1 (every 12 
hours) after I/R (1.5–4.5 days) and evaluated kidneys for tubular 
pathology, renal function, and fibrosis (collagen) in comparison 
with age- and sex-matched PBS-injected mice at 5 days follow-
ing I/R. CSF-1–injected mice had less tubular pathology (dilated 
tubules, casts) in the outer medulla and cortex as compared with 
PBS-injected controls (Figure 1A). Consistent with this finding, we 
detected less fibrosis in the kidney and better renal function (albu-
minuria, blood urea nitrogen [BUN]) in mice injected with CSF-1 
compared with those injected with PBS (Figure 1A). Moreover, we 
detected a decrease in kidney injury molecule 1 (KIM-1), a mole-
cule whose level of expression directly correlates with the degree of 
TEC injury (21), in mice injected with CSF-1 compared with those 
injected with PBS (Supplemental Figure 2). Based on this finding, 
we hypothesized that blocking the CSF-1R following I/R delays 
renal repair. To test this hypothesis, we compared mice injected 
with anti–CSF-1R Abs instead of CSF-1 with age/sex/strain/pro-
cedure-matched mice injected with control Abs (rat IgG) during 
the same time frame following I/R. We detected increased tubular 
pathology, more fibrosis, a greater impairment of renal function 
(albuminuria; Figure 1B), and an increase in KIM-1 expression in 
TECs (Supplemental Figure 2) in mice injected with anti–CSF-1R 
Abs compared with those injected with rat IgG (Figure 1B). This 
suggests that CSF-1 mediates renal repair following I/R.
CSF-1 promotes TEC proliferation and reduces TEC apoptosis following I/R. 
TEC proliferation is a hallmark of renal repair (22). Moreover, 
reducing TEC apoptosis is necessary for healing. Since CSF-1 
mediates renal repair, we hypothesized that CSF-1 promotes TEC 
proliferation and reduces TEC apoptosis following I/R. TEC prolif-
eration reaches an apex on day 3, is on the decline by day 5 (Figure 
1, A and B), and nearly returns to baseline at day 7 (Supplemental 
Figure 1B). Using the same mice examined above, we detected an 
amplified rise (day 3) and a more abrupt decline (day 5) in tubu-
lar proliferation in mice injected with CSF-1 compared with those 
injected with PBS following I/R (Figure 1A). This suggests that 
CSF-1 promotes tubular proliferation after I/R. Moreover, tubu-
lar apoptosis in mice injected with CSF-1 compared with those 
injected with PBS diminished following I/R (day 5). To verify that 
CSF-1 promotes TEC proliferation and reduces TEC apoptosis, 
we blocked the CSF-1R after I/R. Blocking the CSF-1R suppressed 
TEC proliferation (days 3 and 5) and heightened TEC apoptosis 
(day 5) (Figure 1B). This suggests that CSF-1 mediates renal repair 
by promoting TEC proliferation and reducing TEC apoptosis.
The CSF-1R is expressed on TECs and upregulated following in vitro 
stimulation with CSF-1. Since the CSF-1R is expressed on mammary 
epithelial and other nonmacrophage cell types (16, 17), it was pos-
sible that TECs also express the CSF-1R. Therefore, we determined 
CSF-1R transcript and protein expression using cultured TECs, 
first focusing on mouse TECs. We identified CSF-1R mRNA tran-
scripts in primary cultured mouse TECs and the C1 proximal TEC 
cell line (Figure 2A). In comparison, T cells (DO 11.10 line) did 
not express CSF-1R mRNA. To verify CSF-1R expression, we used 
primary TECs derived from Csf1R–/– mice as a negative control. Of 
note, although TECs expressed CSF-1R transcripts, the level of 
expression was far less than in macrophages (primary cultured BM 
macrophages and RAW line). To determine whether CSF-1 upreg-
ulates the expression of CSF-1R transcripts on TECs, we incu-
bated the C1 TEC line with CSF-1. CSF-1 stimulation increased 
CSF-1R transcripts by 24 hours, and expression rose even higher 
by 48 hours (Figure 2A). T cells (DO11.10 line) and macrophages 
(RAW line) served as negative and positive controls, respectively. 
To establish that the CSF-1R protein is expressed on TECs, we 
determined its expression by immunofluorescence staining and 
by Western blotting. The CSF-1R was readily detected on primary 
cultured TECs by immunofluorescence using anti–CSF-1R Abs 
(Figure 2A). We confirmed the specificity of this Ab by using WT 
BM macrophages as a positive control and primary cultured TECs 
derived from Csf1R–/– mice as a negative control. Expression of 
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bands corresponding to both the 135-kDa CSF-1R precursor and 
the mature 165-kDa CSF-1R was also shown in primary cultured 
TECs (C57BL/6 [B6]) and control primary BM macrophages by 
Western blotting (Figure 2A). CSF-1R expression was 3-fold lower 
in the TECs than in the BM macrophages. Thus, the CSF-1R is 
expressed on mouse TECs.
To determine whether human TECs express the CSF-1R, we 
examined CSF-1R mRNA and protein expression in the human 
HK2 TEC line. HK2 cells express CSF-1R mRNA transcripts (Fig-
ure 2B). Consistent with our findings in mice (Figure 2A), T cells 
(Jurkat) did not express CSF-1, and the level of CSF-1R expression 
on macrophages (U937, K562, and HL60 lines stimulated with 
phorbol 12-mayristate 31c acetate [TPA]) was far more robust than 
on TECs (Figure 2B). Similarly, we detected CSF-1R protein in 
human HK2 TEC lysates by Western blotting (Figure 2B). The data 
indicate that both mouse and human TECs express the CSF-1R, 
albeit at lower levels than in macrophages.
Macrophages only partially account for CSF-1–dependent renal repair 
after I/R. Our results thus far indicate that CSF-1 mediates renal 
repair after I/R by promoting TEC proliferation and reducing 
TEC apoptosis and that TECs express the CSF-1R. Since mac-
rophages express the CSF-1R and have been implicated in renal 
repair, it is important to determine the contribution of macro-
phages to CSF-1–mediated repair following injury. Since grow-
ing evidence indicates that a single macrophage marker does not 
exclusively identify macrophages (23), we have used 2 markers to 
identify macrophages, CD68 and F4/80. Using the same proto-
col as depicted in Figure 1, we detected an increase in intrarenal 
macrophages in mice injected with CSF-1 as compared with those 
injected with the vehicle control after I/R (Supplemental Figure 
3). The increase in intrarenal macrophages was selective, since in 
contrast, intrarenal T cells decreased (data not shown). Moreover, 
we detected a decrease in intrarenal macrophages in mice injected 
with anti–CSF-1R Abs as compared with the IgG control after I/R 
(Supplemental Figure 3).
To determine the contribution of macrophages to CSF-1–
dependent renal repair, we used CD11b-DTR mice with a diph-
theria toxin–inducible (DT-inducible) system that transiently 
depletes macrophages (24). Following the injection of DT into 
CD11b-DTR mice at days 1 and 3 after I/R, we evaluated macro-
phages at days 3 and 5. At day 5, the number of intrarenal macro-
phages in CD11b-DTR mice injected with DT was reduced to the 
levels in sham controls (Supplemental Figure 4). In comparison, 
WT mice injected with DT had a robust number of macrophages 
in the kidney after I/R. Since DT markedly ablates macrophages 
in tissues by 12 hours and they are not completely restored until 
4 days (24), we are confident that macrophages are eliminated 
between 1.5 and 5 days after I/R using our DT treatment protocol 
and that the CD11b-DTR mice can be used to evaluate the mac-
rophage contributions. Therefore, we compared the impact of 
CSF-1 on renal repair in macrophage-deficient DT-treated mice 
(response of TECs alone), WT mice (response of macrophages 
and TECs), and WT mice injected with anti–CSF-1 Abs (no 
response of TECs or macrophages). We determined that block-
ing CSF-1 on TECs and macrophages hindered CSF-1–depen-
dent renal tubular repair far more than eliminating macrophages 
alone (Figure 3). While albuminuria was higher in mice without 
macrophages as compared with those with macrophages, block-
ing the CSF-1R resulted in a further rise (Figure 3C). Similarly, 
while fibrosis increased in mice without macrophages, blocking 
the CSF-1R resulted in even more fibrosis (Figure 3D). Strik-
ingly, while CSF-1–dependent tubular proliferation decreased at 
3 and 5 days after I/R in mice without macrophages, blocking 
the CSF-1R reduced proliferation substantially further, nearly to 
baseline (Figure 3E). Although CSF-1–dependent TEC apoptosis 
increased after eliminating macrophages, blocking the CSF-1R 
further amplified the number of apoptotic TECs (Figure 3E). 
Moreover, blocking the CSF-1R increased tubular pathology 
as compared with that in CSF-1 treated mice with or without 
macrophages (Figure 3B). Interestingly, at day 5, removing mac-
rophages alone had not created a detectable impact on tubular 
histopathology, despite the increase of loss of renal function and 
fibrosis (Figure 3C). Taken together, our data indicate that the 
suppression of tubular repair caused by the blocking of CSF-1R 
pathways in the kidney is greater than that caused by eliminating 
macrophages alone. This suggests that another CSF-1R–bearing 
cell contributes to CSF-1–dependent renal repair.
The expression of CSF-1R and CSF-1 on TECs is increased after renal 
injury. Since the CSF-1R is expressed by cultured TECs, we deter-
mined whether the CSF-1R is upregulated on TECs after renal 
injury. For this purpose, we induced renal injury using I/R and 
another model of renal injury, UUO, in MacGreen mice. MacGreen 
mice express a reporter gene for the CSF-1R (EGFP driven by the 
c-fms promoter) (25). CSF-1R expression (Figure 4A) increased on 
TECs during I/R and UUO as compared with on MacGreen sham 
controls, in which expression was barely detected on TECs (Figure 
4A). WT mice served as negative controls. In comparison, EGFP 
staining was far brighter on macrophages than on TECs in I/R, 
UUO, and sham controls. This is consistent with our in vitro data, 
indicating that while TECs express CSF-1R, expression is more 
robust on macrophages. Moreover, we did not detect CSF-1R on 































???? The Journal of Clinical Investigation   http://www.jci.org   Volume 119   Number 8   August 2009
????????????????
 The Journal of Clinical Investigation   http://www.jci.org   Volume 119   Number 8   August 2009 ????
We previously reported that CSF-1 expression in TECs is 
upregulated during renal inflammation (26). To determine wheth-
er CSF-1 and CSF-1R expression is simultaneously enhanced on 
TECs following renal injury (I/R, UUO), we examined the expres-
sion of CSF-1 using TgZ CSF-1 reporter mice (27), which express 
lacZ under the control of the CSF-1 promoter/first intron. CSF-1 
expression, indicated by β-gal staining, was apparent on TECs in 
TgZ mice after I/R and UUO at the same time as CSF-1R expres-
sion (Figure 4B). In comparison, low levels of β-gal staining were 
detected in sham controls (Figure 4B). Thus, CSF-1 and CSF-1R 
were coexpressed on TECs after I/R and UUO. In comparison, 
CSF-1 was sparsely expressed by cells in glomeruli with a mesangial 
and podocyte distribution (Supplemental Figure 5). Since CSF-1 
upregulates CSF-1R in cultured TECs (Figure 2A), it is possible 
that CSF-1 expressed by TECs may enhance CSF-1R expression on 
TECs in response to renal injury in mice.
CSF-1 induces survival/proliferation in TECs after renal injury. The 
expression of both CSF-1 and the CSF-1R are upregulated on 
TECs after renal injury. Since injecting CSF-1 enhances TEC 
proliferation after renal injury, we hypothesized that renal inju-
ry induces CSF-1–dependent autocrine TEC proliferation. To 
test this hypothesis, we first stimulated human HK2 TECs with 
increasing concentrations of CSF-1 and evaluated proliferation 
by 3-(4,5-dimethylthiazol 1-2)-2,5-diphenyltetrazolium bromide 
(MTT) assay. TEC proliferation rose with increasing concentra-
tions of CSF-1 (0, 12, 36 ng/ml), attaining maximum cell density 
at 36 mg/ml (Figure 5A). As expected, blocking the CSF-1R sup-
pressed CSF-1–stimulated TEC proliferation (Figure 5A). This 
result indicates that CSF-1 can stimulate the proliferation of 
cultured human TECs.
To establish that injured TECs express CSF-1 that, in turn, pro-
motes TEC proliferation/survival, we incubated human HK2 TECs 
with actinomycin D, a compound known to injure TECs, and mea-
sured both supernatant CSF-1 and the TEC cell mass. Exposing 
TECs to increasing concentrations of actinomycin D resulted in a 
progressive increase in CSF-1 released into the supernatant (Figure 
5B). Actinomycin D treatment (0.02–0.12 µg/ml) reduced cell num-
bers, but the residual cell mass was proportional to the amount 
of CSF-1 released in response to actinomycin D and was reduced 
to a common low value in cultures containing anti–CSF-1R 
Abs (Figure 5B). We detected similar results to these in human 
HK2 TECs recovering from injury induced by TNF-α/LPS or cis-
platin (Supplemental Figure 6A). We repeated these experiments 
with primary cultured mouse (B6) TECs with comparable findings 
(Supplemental Figure 6, B–D). Furthermore, to exclude the impact 
of genetic background, we repeated these studies using primary 
cultured TECs from C3H/Fej mice and the results were similar 
(data not shown). Taken together, these experiments indicate 
that cultured TECs proliferate in response to CSF-1 and generate 
CSF-1 in response to injury that could contribute to their CSF-1R– 
dependent survival/proliferation following injury.
To determine whether CSF-1 and CSF-1R are coexpressed on 
tubules that proliferate, we evaluated sequential kidney sections 
from patients with tubular injury and impaired renal function 
after kidney transplantation. CSF-1 and CSF-1R expression in 
tubules was highly correlated, and the tubular expression of CSF-1 
correlated with the percentage of proliferating Ki67+ TECs within 
CSF-1+ tubules in these patients (Figure 5C). Tubules containing 
proliferating TECs were those expressing CSF-1 and CSF-1R (Fig-
ure 5C). We verified specificity of the CSF-1 and CSF-1R Abs by 
preabsorbing them with their respective blocking peptides and 
abolishing staining (Figure 5C). In contrast, tubules from normal 
individuals barely expressed either CSF-1 or the CSF-1R and were 
not proliferating (data not shown). Moreover, we pinpointed the 
CSF-1 and CSF-1R expression within the distal and proximal TECs 
and loops of Henle based on location and morphology. In con-
trast, we detected sparse CSF-1 expression in glomeruli (mesan-
gial and podocyte distribution), and CSF-1R expression was even 
more sparse and on only a few glomeruli (Supplemental Figure 
7). Importantly, we determined that CSF-1R+ tubules expressed 
the tyrosine-phosphorylated CSF-1R (Figure 5D). Taken together, 
our results thus far indicate that TEC survival/proliferation is, at 
least in part, regulated by CSF-1 in an autocrine/paracrine man-
ner. Thus, tubular coexpression of CSF-1 and CSF-1R on TECs is 
protective and promotes self replenishment of destroyed TECs.
CSF-1 suppresses TEC apoptosis. In order to more fully examine the 
impact of CSF-1 on survival, we determined whether CSF-1 expres-
sion in injured TECs dampens TEC apoptosis. Adding CSF-1 to 
TECs stimulated with TNF-α/LPS suppressed apoptosis of human 
HK2 TECs, albeit modestly (Figure 6A). Similar results were 
obtained using primary cultured TECs (data not shown). To verify 
that CSF-1 mediates suppression of TEC apoptosis after injury, we 
added anti–CSF-1R Abs along with CSF-1 (Figure 6). Blocking sig-
naling via CSF-1R on TECs eliminated the antiapoptotic impact 
of CSF-1. Moreover, TNF-α/LPS–stimulated TECs expressed suf-
ficient levels of CSF-1 to suppress TEC apoptosis, since blocking 
the CSF-1R increased TEC apoptosis without exogenous CSF-1. 
We detected comparable results using other molecules that injure 
human TECs (actinomycin D, cisplatin) (Supplemental Figure 
8A), and the results were similar using primary human TECs (data 
not shown). These experiments were repeated and the results were 
similar using mouse primary TECs from B6 (Supplemental Fig-
ure 8B) and C3H/Fej mice (data not shown). Taken together, these 
results suggest that autocrine CSF-1–dependent TEC proliferation 
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and antiapoptotic mechanisms are poised to protect tubules after 
injury and to foster repair.
??????????
We now report that CSF-1 promotes tubular repair following 
acute ischemic renal injury. Administration of CSF-1 after renal 
injury fosters improved renal tubular pathology and renal func-
tion, decreases renal fibrosis, accelerates the rate of tubular pro-
liferation, and suppresses tubular apoptosis. Genetic ablation of 
macrophages revealed that macrophages are only partially respon-
sible for CSF-1–dependent renal repair. We also report the finding, 
which we believe to be novel, that the CSF-1R is upregulated on 
TECs during acute renal injury in mice and humans. Moreover, 
signaling via CSF-1R on injured TECs is instrumental in tubular 
self repair. Our studies indicate that CSF-1 is generated by injured 
TECs and upregulates the CSF-1R on TECs. CSF-1 generated by 
TECs binds to the CSF-1R and in turn stimulates tubular prolif-
eration and counters tubular apoptosis. Thus, we have identified a 
CSF-1–dependent, macrophage-independent autocrine/paracrine 
mechanism in tubules that is instrumental in tubular self repair 
following acute renal injury.
CSF-1 initiates renal inflammation and promotes healing. This 
may seem counterintuitive; however, inflammatory and repair pro-
cesses are closely intertwined (2). To understand the CSF-1–depen-
dent mechanism central to renal repair, it is critical to identify the 
intrarenal cells that express CSF-1 and the CSF-1R in conjunction 
with the type and phase of injury being explored. Our prior experi-
mental approaches of deleting (10), overexpressing, and limiting 
expression to an individual CSF-1 isoform in mutant mice (26) and 
of local delivery of CSF-1 into the kidney using genetically modi-
fied TECs (20) established that CSF-1 promotes renal inflamma-
tion. However, these studies were limited to exploring the impact 
of CSF-1 in advance of renal injury in mouse models that fail to 
eliminate the offending agent and do not heal. In support of the 
beneficial impact of CSF-1 on healing, the rate of TEC repair fol-
lowing I/R in CSF-1–deficient (Csf1op/op) compared with WT mice 
is reduced (data not shown). The current findings, using an acute 
renal injury model that leads to healing, indicate that adminis-
tration of CSF-1 fosters renal repair. During the repair phase in 
an injured tissue, damaged tissue may be replaced by regenerating 
parenchymal cells and/or replacing with fibrous tissue (reviewed in 
ref. 28). In our I/R studies, CSF-1 promoted tubular proliferation, 
dampened tubular apoptosis, and lessened fibrosis. The net result 
was a more rapid improvement in renal tubular pathology and res-
toration of renal function. The major source of intrarenal CSF-1 
following renal injury (26) and in particular I/R is the TECs. In 
comparison, the glomeruli express sparse amounts of CSF-1. Since 
macrophages express the CSF-1R and are abundant in the renal 
interstitium adjacent to TECs after I/R, it is reasonable to sug-
gest that the invading macrophages that are recruited to CSF-1– 
rich sites contribute to renal repair. This concept is supported by 
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(13) and the heart (29–31). And in particular, following ischemic 
damage to the kidney, eliminating macrophages using lipoclo-
dronate hinders renal repair (32). In keeping with this concept, 
we detected a greater accumulation of intrarenal macrophages in 
mice injected with CSF-1 that healed more rapidly as compared 
with controls. By genetically ablating macrophages, our studies 
indicate that macrophages only partially contribute to this CSF-1– 
dependent renal repair. Thus, we must broaden our view of the 
CSF-1–dependent mechanisms leading to renal repair to include 
renal parenchymal cells expressing CSF-1R. We now report that 
TECs express low levels of CSF-1R but that, following renal injury 
in mice and humans, these receptors are upregulated and expres-
sion of CSF-1 is elevated. Not surprisingly, the expression of CSF-1 
and CSF-1R is sparse and virtually nonexistent, respectively, in 
glomerular parenchymal cells. This is consistent with renal injury 
being largely confined to TECs rather than to glomeruli after an 
ischemic insult. Heightened coexpression of CSF-1 and CSF-1R 
on TECs is in keeping with findings in other epithelial cells. CSF-1 
and CSF-1R are abundantly coexpressed on breast, ovarian, uter-
ine, and prostate epithelial carcinomas and in mammary epithe-
lial cells during pregnancy (15, 33, 34). Our findings suggest that 
the spectrum of epithelial cells coexpressing CSF-1 and CSF-1R 
may expand to cells exposed to injury and inflammation. Thus, it 
is tempting to speculate that a CSF-1–mediated mechanism may 
contribute to epithelial cell repair in a broad range of tissues.
There is growing evidence that, following renal injury, tubules 
express multiple molecules central to self repair and self protec-
tion. Some of these pathways promote autocrine/paracrine TEC 
proliferation and others counter TEC apoptosis. For example, the 
heparin-binding EGF-like growth factor (HB-EGF) is induced in 
the kidney after acute tubular injury (I/R in rats) and may act as 
an autocrine/paracrine growth factor involved in proliferation of 
TECs and the subsequent repair of the kidney (35, 36). Macro-
phage-stimulating protein (MSP) and its ligand RON (37), which 
are weakly coexpressed on TECs and are upregulated following 
TEC injury, may resemble the regulation by CSF-1/CSF-1R, as in 
vitro, MSP stimulates TEC proliferation and confers resistance to 
cisplatin-induced TEC apoptosis. Our in vivo and in vitro findings 
in mice and humans clearly indicate that the CSF-1/CSF-1R medi-
ates tubular self repair and self protection by promoting autocrine/
paracrine TEC proliferation and countering TEC apoptosis.
CSF-1 lessened interstitial fibrosis following I/R. The pathogen-
esis of interstitial fibrosis is controversial. One theory is that toxic 
damage to kidney tubules triggers interstitial fibrosis (38). Damaged 
tubules either directly or indirectly cause the release of molecules 
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(39). These myofibroblasts in turn generate collagen. Our findings 
indicate that macrophage-dependent and -independent CSF-1–
mediated mechanisms suppress interstitial fibrosis, since blocking 
the CSF-1R increases fibrosis far more than eliminating macro-
phages alone. This implies that events dependent on signaling via the 
CSF-1R on TECs may release molecules that suppress fibrosis. This 
intriguing concept will require further studies to identify CSF-1R+ 
TEC mechanisms linked to renal interstitial fibrosis.
In conclusion, CSF-1 mediates renal repair after ischemic inju-
ry. While macrophages contribute to CSF-1–dependent renal 
repair, we have uncovered a CSF-1–dependent tubular auto-
crine/paracrine mechanism that aids in tubular regeneration 
and counters tubular destruction following acute renal injury. 
This finding has potential therapeutic application for a broad 
range of kidney diseases.
???????
Mice
We purchased B6, C3H/Fej, and MRL/MpJ-Faslpr/Faslpr (MRL-Faslpr) mice 
from The Jackson Laboratory. Csf1r+/– mice on the C3/B6 background (40) 
and transgenic mice (FVB) expressing lacZ under the control of CSF-1 
promoter and the first intron [TgN(Csf1-Z)Ers7/+], referred to as TgZ 
mice (27), were developed in the specific pathogen–free animal facility of 
the Albert Einstein College of Medicine. Transgenic mice (B6 × CBAF1) 
expressing EGFP under the control of the CSF-1R (c-fms) promoter and 
first intron (Tgfms-EGFP), referred to as MacGreen mice (FVB/B6 mixed 
background), were provided by D.A. Hume, University of Edinburgh, 
Edinburgh, Scotland (25). We backcrossed the TgZ and MacGreen mice 
onto the B6 background for 7 generations. These mice are referred to as 
MacGreen;B6 and TgZ;B6, respectively. We also used transgenic Tg(ITGAM-
DTR/EGFP)34Lan mice (FVB background), referred to as CD11b-DTR 
mice (The Jackson Laboratory) with a DT-inducible system that transient-
ly depletes macrophages. Mice were housed and bred at Harvard Medical 
School. Use of mice in this study was reviewed and approved by the Stand-
ing Committee on Animals in the Harvard Medical School in adherence 
to standards set in the Guide for the care and use of laboratory animals (NIH 
publication no. 86-23. Revised 1996).
I/R
We anesthetized mice and exposed the left kidney through a flank inci-
sion. We induced ischemia by clamping the renal pedicle with nontrau-
matic microaneurysm clamps (Roboz). We removed the clamps after 30 
minutes. The body temperature was controlled at 36.6–37.5°C throughout 
the procedure. We removed the obstructed kidney and fixed, sectioned, 
and analyzed tissue as previously described (26). Male mice were exclusively 
used for I/R experiments.
Ab/cytokine administration
We injected mice (i.p.) every 12 hours with purified recombinant human 
CSF-1 (50 µg/kg/body weight) or daily with CSF-1R Abs (AFS98, 
50 mg/kg/body weight; rat monoclonal anti-mouse Abs) (41) beginning 
at 1.5 days after I/R and ending at various time points during I/R. CSF-1 
was a gift from Chiron, and the AFS98 hybridoma was a gift of Shin-Ichi 
Nishikawa (RIKEN Center for Developmental Biology, Kobe, Japan). Mice 
receiving PBS and rat IgG were used as controls for CSF-1– and CSF-1R 
Ab–injected mice, respectively.
Renal histopathology
We fixed kidneys in 10% neutral buffered formalin, embedded them in 
paraffin, and stained paraffin sections (4 µm) with periodic acid-Schiff 
reagent. Kidney pathology was assessed as previously described (42).
Collagen detection
We stained paraffin sections after rehydration in picrosirius red solution 
for 1 hour and rinsed (×2) with acidified water. We dehydrated and mount-
ed the sections and analyzed the amount of stain using a Nikon Eclipse 
E1000 upright fluorescence microscope and Adobe Photoshop CS2.
Renal function
We measured BUN and albuminuria as previously described (42).
Isolation of primary TECs
We isolated and cultured TECs derived from B6 mice as previously 
reported (43).
Proliferation
Immunohistochemistry. We stained paraffin sections using a primary Ab 
against rabbit anti-human/mouse Ki67 (SP6; Lab Vision, Thermo Scien-
tific) to identify proliferating TECs.
MTT assay. We cultured HK2 cells and primary isolated TECs (B6) in 
96-well plates (5 × 103 cells/well) for 12 hours and stimulated these cells for 
72 hours with human recombinant CSF-1 at various concentrations (12, 
36, 60, 120, and 240 ng/ml). To verify specificity by blocking the CSF-1R, 
we stimulated cells with CSF-1 (10 and 20 ng/ml) in combination with 
CSF-1R Abs (25 and 50 ng/ml; Santa Cruz Biotechnology Inc.) for 72 
hours. Furthermore, we stimulated cultured HK2 cells, primary mouse 
TECs with varying concentrations of human recombinant CSF-1 (5, 20, 
39, and 78 ng/ml) in combination with actinomycin D (0.02, 0.04, 0.08, 
and 0.12 µg/ml), cisplatin (1 µg/ml) or TNF-α (3, 6, 15, and 30 ng/ml), 
and LPS (6.3, 12.5, 25, and 50 ng/ml) (Sigma-Aldrich). We analyzed pro-
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Cell lines
Cell lines were used and cultured as previously described. Mouse cell lines 
were as follows: immortalized proximal TEC line (C1) (44), CD4+ T cell 
line (DO11.10) (45), and monocytic-macrophage cell line (RAW 264.7) 
(46). Human cell lines were as follows: immortalized proximal TEC line 
(HK2) (47), leukemic monocyte lymphoma cell line (U937) (48), erythro-
myeloblastoid leukemia cell line (K562) (49), promyelocytic leukemia cell 
line (HL60) (50), and immortalized T cell line (Jurkat) (51).
CSF-1R transcript expression
We analyzed the CSF-1R expression in primary TECs, BM macrophages, 
and cell lines using real-time, 2-step, quantitative PCR as previously 
described (RTQ-PCR) (52). The mRNA levels were normalized to those 
of GAPDH. We used the following PCR primers: mouse: GAPDH; sense, 
5′-CATGGCCTCCAAGGAGTAAG-3′, antisense, 5′-CCTAGGCCCCTCCT-
GTTATT-3′; and CSF-1R; sense 5′-CTACTGCTGTTGCTGCTCTTGT-3′, 
anti-sense 5′-CGGCTCCTAGAGTCTTACCAAA-3′; and human: GAPDH; 
sense, 5′-CCCTCAACGACCACTTTGTCA-3′, antisense, 5′-TTCCTCTT-
GTGCTCTTGCTGG-3′; and CSF-1R; sense 5′-TGAGCAAGACCTGGA-
CAAGGA-3′, antisense 5′-CCATTGGTCAACAGCACGTTA-3′.
Immunoprecipitation and Western blot
Cell lines, primary isolated TECs, and BM macrophages grown on 10-cm 
plates were collected when confluent. Stimulation with TPA (1 µM) was 
done for 24 hours in the human cell line, followed by stimulation with 
CSF-1 (100 ng/ml) for 1, 3, 5, and 10 minutes. Primary isolated TECs and 
BM macrophages were stimulated with CSF-1 (100 ng/ml) for 1, 3, 5, and 
10 minutes. We resuspended the cell pellets in lysis buffer (2% NP-40, 
10 mM Tris–HCl, 50 mM NaCl, 30 mM Na4P2O7, 50 mM NaF, 1 mM 
Na3VO4, 5 µM ZnCl2, 1 mM benzamidine, 20 µg/ml leupeptin, and 10 µg/ml 
aprotinin, pH 7.2). We lysed cells by successive freezing and thawing in 
liquid nitrogen (×3). Cell lysates were passed through a 25-gauge needle 
(×5) followed by centrifugation for 20 minutes at 10,000 g, and super-
natants were stored at –80°C until analysis. For immunoprecipitation, 
NP-40 lysates were incubated with 5 µg of rabbit anti-mouse CSF-1R 
C-terminal domain peptide Abs (C15; ref. 53) and 20 µl protein A–sep-
harose 4B beads (Zymed) overnight at 4°C with continuous mixing and 
then centrifuged at 13,000 g at 4°C for 30 seconds. The supernatant was 
removed, and the beads were washed at 4°C with 1 ml wash buffer (lysis 
buffer containing 0.5% NP-40 without leupeptin and aprotinin) 5 times 
and 200 µl double-distilled water once; proteins were eluted with 10 µl 
3% SDS sample buffer at 65°C for 10 minutes. SDS-PAGE (10% acryl-
amide) and Western blotting with rabbit anti-mouse–CSF-1R IK Abs (54) 
were carried out as previously described (53).
CSF-1R and CSF-1 expression
Immunofluorescence: in vitro. We isolated and cultured TECs and BM macro-
phages from B6 mice as previously described (43, 55). Cells (1 × 104/well) 
were stimulated with mouse CSF-1 (10 ng/ml; PeproTech) for 48 hours. 
We fixed cells with methanol for 5 minutes on coverslips and incubated 
them with rabbit anti-mouse CSF-1R IK Abs (generated by R. Stanley) for 
1 hour at RT. We detected CSF-1R by incubating cells with biotinylated 
goat-anti-rabbit Abs (Vector Laboratories) for 1 hour, followed by strepta-
vidin-FITC (eBioscience) for 30 minutes. We mounted the coverslips with 
Vectashield (Vector Laboratories) and analyzed them using a Nikon Eclipse 
E1000 upright fluorescence microscope.
Immunofluorescence: in vivo. To identify CSF-1R–bearing cells and CSF-1 
expression in the kidney, we fixed, prepared, and analyzed kidneys from the 
mutant MacGreen and TgZ reporter gene mice, respectively, as previously 
described (25, 26).
Immunohistochemistry: paraffin sections. We deparaffinized and rehydrated 
serial sections (4 µm). Antigen retrieval was performed by immersion in 
citrate buffer (pH 6.0) at 95°C for 45 minutes. Endogenous peroxidase 
activity was blocked by incubation with 3% H202 in methanol. We blocked 
the nonspecific binding of avidin and biotin using an avidin/biotin block-
ing kit according to the manufacturer’s instructions (Vector Laboratories). 
After we blocked the nonspecific binding of goat or rabbit Abs by incu-
bating with 10% normal goat or rabbit serum, respectively, we incubated 
the sections with either goat anti-human CSF-1 Abs (N-16; Santa Cruz 
Biotechnology Inc.) or rabbit anti-human phospho–M-CSFR Tyr 723 
Abs (49C10; Cell Signaling Technology) at 4°C overnight. We detected 
these primary Abs by incubation with biotinylated rabbit anti-goat Abs, 
followed by peroxidase-conjugated ABC solution and development with 
3′3-diaminobenzidine (Vector Laboratories) (CSF-1) or by use of the EnVi-
sion+ System (Dako) for rabbit primary Abs according to the manufactur-
er’s instructions. Sections were counterstained with Mayer’s Hematoxylin 
(Sigma-Aldrich). We confirmed specificity by using specific blocking pep-
tides for CSF-1 and CSF-1R (Santa Cruz Biotechnology Inc.) and replacing 
the primary Abs with goat IgG for CSF-1 and rabbit IgG (eBioscience) for 
the other Abs. We determined the number of positive cells in 10 randomly 
selected high-power fields and evaluated the corresponding areas within 
serial sections for the correlation analysis.
Immunohistochemistry: frozen sections. We stained frozen kidney sections 
(4 µm) for the presence of macrophages and T cell populations, using 
anti-mouse CD68 Abs (FA-11; AbD Serotec), anti-mouse CD4 Abs (RM 
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We identified apoptotic cells using anti-cleaved caspase-3 (Asp175) (Cell 
Signaling Technology) (56).
KIM-1 expression
Cryosections (7 µm) were mounted on Fisher Superfrost Plus (Fisher Sci-
entific) microscope slides, air-dried, and treated for immunofluorescence 
using standard techniques. The polyclonal anti–KIM-l antisera R9 was 
used at a 1:200 dilution (21). Cy3-conjugated anti-rabbit secondary 
Abs were from Dako. Sections were mounted in Vectashield containing 
4',6-diamino-2-phenylindole (Vector Laboratories). Confocal immunoflu-
orescent images were obtained using a Nikon C1 D-Eclipse confocal micro-
scope. Projection images were generated from 8 Z-stack images acquired 
at 0.1 µm steps. To allow comparison among sections, all confocal settings 
were kept constant among sections.
Apoptosis
We cultured human HK2 cells and primary mouse TECs (B6) in 6-well 
(apoptosis assay) or 96-well (proliferation assay) plates (5 × 104/well) 
for 12 hours and stimulated these cells with varying concentrations of 
human recombinant CSF-1 (5, 20, 39, and 78 ng/ml) in combination with 
actinomycin D (0.05 µg/ml), cisplatin (1 µg/ml) or TNF-α (3, 6, 15, and 
30 ng/ml), and LPS (6.3, 12.5, 25, and 50 ng/ml). After 72 hours, we 
assessed apoptosis by flow cytometry using an annexin V–FITC–PI kit (BD 
Biosciences) according to the manufacturer’s instructions.
Renal biopsy specimens
Biopsy sections (discarded tissues) from kidney transplants were provided 
by the Department of Pathology (J. Kriegsmann), Johannes-Gutenberg 
University. Kidneys were biopsied between 0 and 2 months after engraft-
ment due to impaired renal function. The tubules were abnormal in these 
biopsies and included at least one of the following: dilatation, vacuolariza-
tion, hyaline casts, and/or atrophy. Leukocytes were noted in the intersti-
tium, and there was a mild increase in mesangial matrix within glomeruli.
CSF-1 ELISA
To quantify the levels of CSF-1 in supernatants, we evaluated samples 
using an ELISA as previously described (57).
Deleting macrophages
To delete macrophages, we injected CD11b-DTR mice i.v. with DT (Sigma-
Aldrich) at 20 ng/g body weight.
Statistics
Data represent the mean ± SEM and were prepared using GraphPad 
Prism software, version 4.0. We used the nonparametric Mann-Whitney 
U test to evaluate P values. P < 0.05 was considered significant. For cor-
relation analysis, we used Spearman’s correlation calculation.
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